4.7 Article

Glycometabolism-related gene signature of hepatocellular carcinoma predicts prognosis and guides immunotherapy

Journal

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fcell.2022.940551

Keywords

hepatocellular carcinoma; glycometabolism; prognosis; immunotherapy; nomogram

Funding

  1. National Natural Science Foundation of China [81874435, 81902895]
  2. Dengfeng Talent Support Program of Beijing Municipal Administration of Hospitals [DFL20191803]
  3. Special Fund of Capital Health Research and Development [2020-2-2173]
  4. Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support [ZYLX202127]
  5. Beijing Natural Science Foundation [M21007]

Ask authors/readers for more resources

A novel glycometabolism-related risk score was constructed to predict prognosis and immunotherapy strategies in hepatocellular carcinoma (HCC) patients. The risk score effectively distinguished the prognosis, molecular and immune-related characteristics of HCC patients, and may provide a new strategy for individualized treatment.
Hepatocellular carcinoma (HCC) is a severe cancer endangering human health. We constructed a novel glycometabolism-related risk score to predict prognosis and immunotherapy strategies in HCC patients. The HCC data sets were obtained from the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) database, and the glycometabolism-related gene sets were obtained from the Molecular Signature Database. The least absolute contraction and selection operator (LASSO) regression model was used to construct a risk score based on glycometabolism-related genes. A simple visual nomogram model with clinical indicators was constructed and its effectiveness in calibration, accuracy, and clinical value was evaluated. We also explored the correlation between glycometabolism-related risk scores and molecular pathways, immune cells, and functions. Patients in the low-risk group responded better to anti-CTLA-4 immune checkpoint treatment and benefited from immune checkpoint inhibitor (ICI) therapy. The study found that glycometabolism-related risk score can effectively distinguish the prognosis, molecular and immune-related characteristics of HCC patients, and may provide a new strategy for individualized treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available